At Gameto, we are driven by one mission: to revolutionize women's healthcare. Today, I am proud to share a bit about our journey and how we achieved the world’s first live birth using Fertilo, our groundbreaking in vitro oocyte maturation product made from stem cell technology. This achievement is not just a technical breakthrough but a promise of better, safer, and more accessible fertility options for millions of families worldwide.
The Science Behind Fertilo
Fertilo was born from an ambitious vision, which was to overcome the limitations of traditional assisted reproductive technologies (ART). The cornerstone of our innovation lies in leveraging induced Pluripotent Stem Cells (iPSCs) to mature eggs outside the body, eliminating the need for high-dose hormonal stimulation cycles and reducing the side-effects women often face from the traditional hormone injection protocol.
By collaborating with REPROCELL, a leader in stem cell technologies, we utilized their StemRNATM Clinical Seed iPSCs to engineer ovarian support cells (OSCs) with high purity and potency. These OSCs mimic the natural ovarian environment in a dish, providing the essential support needed for egg maturation in vitro.
This process not only enhances the efficiency and safety of in vitro fertilization (IVF) but also mitigates many of the physical and emotional burdens faced by patients undergoing traditional hormone therapies. Given that currently on average it takes an IVF patient between two and three cycles for a live birth, easier and faster cycle repeatability could be the difference-maker that helps patients reach their family-building dreams.

Clinical Stem Cell Services
We provide iPSC and MSC manufactruing services for cell therapy projects
A Safer and More Accessible Future
Infertility treatments have often been fraught with challenges: lengthy processes, significant side effects, and high costs. Fertilo addresses these pain points by offering a potentially safer and better alternative. The technology enables minimal hormonal stimulation cycles, significantly reducing patient discomfort and associated risks.
Fertilo has been designed with accessibility in mind. By streamlining the egg maturation process and reducing dependence on costly infrastructure, we ultimately aim to make fertility care available to a broader patient population.
We are pleased to announce that Fertilo has secured regulatory clearance in multiple countries worldwide, including, most recently, Australia. Through our partnership with IVFAustralia (IVFA), part of the Virtus Health group, Fertilo will now be available to patients at select IVFA and Virtus clinics. As one of the top five assisted reproductive services providers globally, Virtus Health’s extensive network enables us to bring Fertilo to more patients, expanding access to cutting-edge fertility solutions. Additionally, Fertilo has gained traction in key markets across Latin America, further advancing our mission to make a global impact on reproductive health.
A Baby Born Through Innovation
This milestone live birth is a testament to the transformative potential of our technology in fertility care. The success has been documented in the manuscript, “Reproducible differentiation of pure ovarian support cells from clinical grade hiPSCs as a novel infertility treatment,” which highlights the scalability and precision of our approach.
The parents involved in this historic moment embody the hopes of countless families who dream of building their own. Their journey inspires us to continue pushing boundaries and finding solutions to the most pressing challenges in women’s health.
As we advance into Phase 3 clinical trials in the United States, Fertilo is just the beginning. At Gameto, we envision a future where women have access to comprehensive reproductive care at every stage of their lives.
This achievement also underscores the importance of collaboration.
I extend my deepest gratitude to our partners at REPROCELL, whose advanced StemRNA platform was instrumental in making this milestone possible.
The journey to revolutionize fertility care is far from over. Gameto is committed to expanding Fertilo’s reach and exploring new applications of iPSC technology to address other critical areas in women's health. From reducing the physical toll of fertility treatments to providing new hope for those facing infertility, our work is driven by the belief that every woman deserves access to the best possible care.
Together, we can shape a future where the convergence of science and technology redefines what’s possible in women’s health.